Long-term follow-up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and trastuzumab (T) for HER2-altered (HER2+) metastatic breast cancer (MBC).
Giuseppe Gullo
No relevant relationships to disclose
Monica Zuradelli
No relevant relationships to disclose
Francesco Sclafani
No relevant relationships to disclose
Josephine Ballot
No relevant relationships to disclose
Anne Marie Defrein
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
John Crown
Honoraria - Roche